Ruben Niesvizky, M.D.

Medical Oncology
Ruben Niesvizky

As the Director of the Multiple Myeloma Service at the Center of Excellence for Lymphoma and Myeloma at New York Presbyterian Hospital-Cornell Medical Center, my duties will focus on providing outstanding clinical care and coordinating a world class clinical translational research program. Prestigious investigators have joined forces to create one of the leading centers for myeloma research. I have no doubt that this cooperative effort forms one of the best myeloma research groups on the World.

My 20 years of experience as a myeloma physician has helped me to appreciate how important it is to treat patients in the context of a comprehensive program. New York Presbyterian Hospital has an outstanding Bone Marrow Transplant Service (a treatment modality often used for myeloma patients), performing more than 100 transplants per year. It has also been rated the best in the world in the fields of cardiology (heart), neurosurgery and nephrology (kidney). The Hospital for Special Surgery, also part of the New York Presbyterian-Weill Cornell system, has an outstanding group of orthopedic surgeons that support a new comprehensive bone disease program. In addition, as part of our continuing search for more effective therapeutic options, we offer multiple clinical trials utilizing promising new drugs and medical procedures for treating myeloma and related hematological disorders.

The ultimate goal is to find the cure for multiple myeloma. The establishment of a strong Multiple Myeloma Center of Excellence at New York Presbyterian Hospital Weill Cornell Medical Center is an important step towards the accomplishment of this goal.

For more information, please click here: http://www.Myelomacenter.org

Dr. Niesvizky is Associate Professor of Medicine at Weill Medical College of Cornell University and at NewYork Presbyterian Hospital/Weill Cornell Medical Center in Manhattan. He also serves as Director of the Multiple Myeloma Service at the Center of Excellence for Lymphoma and Myeloma at NewYork Presbyterian Hospital/Weill Cornell Medical Center. After receiving a medical degree from National University of Mexico, Dr. Niesvizky did a research fellowship in cell biology-granulomonopoiesis and an internal medicine residency at the National Institute of Nutrition in Mexico. He then completed fellowships in New York: one (hematology) at Mount Sinai Medical Center and one (hematology/medical oncology) at Memorial Sloan-Kettering Cancer Center. He has written more than 50 articles, editorials, chapters, and abstracts published in journals such as New England Journal of Medicine, Blood and Leukemia & Lymphoma, most recently on topics such as the treatment of myeloma and Waldenstrom's macroglobulinemia. He is the recipient of various grants and awards from the National Cancer Institute, including a K23 award and two translational research grants. He recently received the 2007 Investigator Award of the Michael Wolk Heart Foundation. A frequent lecturer, Dr Niesvizky regularly presents at annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, of which he is also a member. He is an active participant in clinical trials of promising new drugs and medical procedures for the treatment of myeloma, lymphoma, and related hematologic disorders.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

Niesvizky R, et al: Linfomas cutaneos de celulas T. Rev Fac Med (Mex) 27:25. 1984

Lopez Karpovitch JX, Niesvizky R, et al: Comparison of colony-stimulating activities for evaluating in vitro granulo-monopoiesis in normal subjects and in patients with myeloid leukemia. Rev Invest Clin (Mex) 37:323, 1985

Ladanyi M, Feiner H, Niesvizky R, Michaeli J: Proto-oncogene analysis in multiple myeloma. Am J Pathol 141:949, 1992.

Niesvizky R, Siegel D, Michaeli J: 2-Chlorodeoxyadenosine for multiple myeloma. Blood 81:868, 1993.

Niesvizky R, Calandri C, Patel ND, Xao SL, Potter BJ, Rand JH: Von Willebrand Factor binding to collagen in end stage renal disease patients. J Lab Clin Med 123:137-42, 1994.

Niesvizky R, Siegel D, Busquets X, Nichols G, Muindi J, Warrell RP, Michaeli J: Hypercalcemia and increased serum interleukin-6 levels induced by all-transretinoic acid in patients with multiple myeloma. Brit J Haematol 89:217-218, 1995.

Michaeli J, Niesvizky R, Siegel D, Ladanyi M, Lieberman P, Filippa D: Proteinaceous (Angiocentric Sclerosing) lymphadenopathy: A polyclonal systemic, non-amyloid deposition disorder. Blood 83:1159-1162, 1995

Bowne W, Lewis J, Filippa D, Niesvizky R, Brooks A, Burt M, Brennan M: The management of regional and multicentric Castleman's Disease. Cancer 85(3):706-17, 1999.

Niesvizky R, Louie D, Zhu A, Michaeli J: EBV-lymphoma after cladribine treatment for Waldenstrom's macroglobulinemia. (letter). New Eng J Med 341(1):55, 1999 Jul 1.

Zhu A., Niesvizky R, Filipa D, Hedrick E, Fata F, Filippa D, and Michaeli J: Extensive bone marrow necrosis associated with multiple myeloma (letter). Leukemia. 13 (12): 2118-20, 1999 Dec.

Niesvizky R, Siegel D, Glassman J, Straus D, Fine J, Lyons L and Michaeli J: Impact of Early Response to sequential high dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features. Leukemia and Lymphoma, 2002, 43 (3), 607-612

Niesvizky R, Choy CG and Michaeli J: Extended Survival in Advanced Stage Multiple Myeloma Patients Treated with Gallium Nitrate. Leukemia and Lymphoma, 2002, 43 (3), 603-605

Niesvizky R, Siegel D, Michaeli J: Biology and treatment of multiple myeloma. Blood Reviews 7:24-33, 1993.

Schuller D, Niesvizky R. Clinical Simulations in the Management of Herpes Virus Infection in the Immunocompromised Cancer Patient. Norwalk, CT: Medical Age Publishing 1994

Choy GC, Niesvizky R, Michaeli J: Multiple myeloma-Treatment Recommendations. Clin Immunother, 4:346-360, 1995.

Niesvizky, R, Warrell RP: Pathophysiology and management of bone disease in multiple myeloma. Cancer Invest, 15:85-90, 1997.

Niesvizky, R: Dr Joseph (Yosi) Michaeli, New York, USA. Obituary. Leukemia and Lymphoma, 2002, 43 (3), 683-684

Niesvizky, R: Gallium Nitrate in Multiple Myeloma: Prolonged Survival in a Cohort of Patients With Advanced-Stage Disease, Seminars in Oncology. 30(2 Suppl 5):20-4, 2003 Apr.

Niesvizky R , Martinez Banos Deborah M: Nuevas Alternativas Terapeuticas en Mieloma Multiple. In Mieloma Multiple, Eds. Jorge Vela Ojeda, et al. Ed. Elsevier, ISBN 970-9793-12-8, 2006

Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky R and Michaeli J: BLTD (Clarithromycin (Biaxin), Low dose Thalidomide and Dexamethasone) for the treatment of myeloma and Waldenstrom#146;s Macroglobulinemia. Leukemia and Lymphoma, 2002, 43(9) pp 1777-1782

Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenstrom#146;s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol.2003 Apr; 30(2):270-4.

Lane JM, Hong R., Koob J, Kiechle T., Niesvizky R, Pearse R, Siegel D, Poynton AR: Kyphoplasty enhances function and structural alignment in multiple myeloma. Clinical Orthropedics and Related Research, September 2004;(426):49-53.

Jagannath S. Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC. A Phase II Study of Two Doses of Bortezomib in relapsed or Refractory Myeloma. Br J Haematol 2004 Oct;127(2):165-72

Loic Vincent, David K Jin, Kofi Shido, Matthias A. Karajannis, Kathryn Walsh, Andrea T. Hooper, Ruben Niesvizky, Shahin Rafii. Fetal stromal-dependent paracrine and intracrine VEGF-A/VEGFR-1 signaling promotes proliferation and mortality of human primary myeloma cells. Cancer Res. 2005 Apr 15;65(8):3185-92

Achin A Jungbluth, Scott Ely, Maurizio DiLiberto, Ruben Niesvizky, Barbara Williamson, Denise Frosina, Yao-Tseng Chen, Nina Bhardwaj, Selina Chen-Kiang, Lloyd Old, Hearn Jay Cho. The Cancer Testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma cell proliferation Blood. 2005 Jul 1;106(1):167-74. 2005 Mar 10.

John P. Leonard, Morton Coleman, Jamie Ketas, Michelle Ashe, Jennifer Fiore, Richard Furman, Ruben Niesvizky, Tsiporah Shore, Amy Chadburn, Heather Horne, Jacqueline Kovacs, Cliff Ding, William Wegener, Ivan Horak, and David Goldenberg. Combination antibody therapy with epratuzumab (humanized anti-CD22 antibody) and rituzimad (chimeric anti-CD20 antibody in relapsed/refractory non-Hodgkins lymphoma (NHL), J Clin Oncol. 2005 Jun 13

Scott Ely, Maurizio Di Liberto, Ruben Niesvizky, Linda B. Baughn, Hearn J. Cho, Eunice N. Hatada, Daniel M. Knowles, Joseph Lane and Selina Chen-Kiang. Mutually exclusive Cdk-4-Cyclin D1 and Cdk6-Cyclin D2 pairing inactivates Rb and promotes cell cycle dysregulation in multiple myeloma cells. Cancer Res. 2005 Dec 15;65(24):11345-53

James R. Berenson, Sundar Jagannath, Bart Barlogie, David T. Siegel, Raymond Alexanian, Paul G. Richardson, David Irwin, Melissa Alsina, S. Vincent Rajkumar, Gordon Srkalovic, Seema Singhal, Steven Limentani, Ruben Niesvizky, Dixie L. Esseltine, Elizabeth Trehu, David P. Schenkein, Kenneth Anderson.. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005 Nov 15;104(10):2141-8.

Alan D. Dosik, Morton Coleman, Lale Kostakoglu, Richard R. Furman, Jennifer M. Fiore, Daniel Muss, Ruben Niesvizky, Tsiporah Shore, Michael W. Schuster, Patricia Stewart, Shankar Vallabhajosula, Stanley J. Goldsmith, John P. Leonard. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma Cancer 2006 Feb 1;106(3):616-22

Linda B. Baughn, Maurizio Di Liberto, Kaida Wu, Peter L. Toogood, Tracey Louie, Rachel Gottschalk, Ruben Niesvizky, Hearn Cho, Scott Ely, Malcolm A.S. Moore and Selina Chen-Kiang. A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6 . Cancer Research 66, 7661-7667, August 1, 2006

Ruben Niesvizky, Tara Naib, Paul Christos, David Jayabalan, Jessica R. Furst, Jessica Jalbrzikowski, Faiza Zafar, Tomer Mark, Richard Lent, Roger Pearse, Scott Ely, John Leonard, Madhu Mazumdar, Selina Chen-Kiang and Morton Coleman. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment naïve patients undergoing front-line lenalidomide and dexamethasone therapy Br J Haematology 138, 640-643, 2007

Edward A. Stadtmauer, Sagar Lonial, David H. Vesole, Rafat Abonour, Melissa Alsina, Ashraf Badros, Raymond Comenzo, Brian Durie, Sergio Giralt, Mohamad Hussein, Andrzej Jakubowiak, Jayesh Mehta, Ruben Niesvizky, Robert Orlowski, David Siegel, Seema Singhal, Robert Vescio, Michael Wang, Maurizio Zangari, Nikhil C. Munshi A Practical Guide to Achieving and Maintaining the Best Response to Lenalidomide in Multiple Myeloma: Roundtable. Proceedings Clinical Advance in Hematology and Oncology 2007 Oct;5(10 Suppl 15):1-24.

Donna M. Weber, Christine Chen, Ruben Niesvizky, Michael Wang, Andrew Belch, Edward Stadtmauer, David Siegel, Ivan Borrello, S. Vincent Rajkumar, Asher Alban Chanan-Khan, Sagar Lonial, John Patin, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert Knight. Randomized, Phase III, Placebo-Controlled Trial of Lenalidomide in Combination With High-Dose Dexamethasone for Relapsed or Primary Refractory Multiple Myeloma. New Eng J Med, 2007 Nov 22;357(21):2133-42

Ruben Niesvizky, Déborah M. Martínez-Baños, Maria T. De Sancho, Madhu Mazumdar, Jessica R. Furst, John P. Leonard, David S. Jayabalan, Morton Coleman. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia Lymphoma, 2007 Dec; 48(12):2330-7.

Mazumder A , Kaufman J, Niesvizky R , Lonial S , Vesole D.H., Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008 Jun;22(6):1280-1

A. Palumbo, S.V. Rajkumar, M. Dimopoulos, P Richardson, J. San Miguel, B Barlogie, J-L. Harousseau, J Zonder, M Cavo, M Zangari, M. Attal, A Belch, S. Knop, D Joshua, H. Ludwig, D Vesole, J Blade, R Kyle, J Westin, D. Weber, S. Bringhen, R. Niesvizky, A Waage, M. von Lilienfeld-Toal, S Lonial, G Morgan, RZ Orlowski, K Shimizu, K. Anderson, M Boccadoro, B. Durie, P. Sonneveld, M. Hussein, on behalf of the International Myeloma Working Group. Recommendation for the prevention of thalidomide and lenalidomide associated thrombosis in myeloma: International Myeloma Working Group consensus statement. Leukemia. 2008 Feb;22(2):414-23. Epub 2007 Dec 20.

Paul G. Richardson, Ruben Niesvizky, Kenneth C. Anderson, Joan Bladé. When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. J Natl Cancer Inst. 2008 Mar 5;100(5):373. Epub 2008 Feb 26.

Ruben Niesvizky, David S. Jayabalan, Jessica R. Furst, Paul J. Christos, Hearn J. Cho, Roger N. Pearse, Faiza Zafar, Karen Pekle, Richard Lent, Scott Ely, David K. Jin, Tsiporah Shore, Jeffrey Tepler, John Harpel, Michael Schuster, Susan Mathew, John P. Leonard, Selina Chen-Kiang, Madhu Mazumdar, Morton Coleman. BiRD (Biaxin®[clarithromycin]/Revlimid®[lenalinomide]/Dexamethasone) Combination Therapy Results in High Complete and Overall Response Rates in Treatment-Naïve Symptomatic Multiple Myeloma Patients. Blood, Feb 2008, Vol. 111, No. 3, pp. 1101-1109.

Morton Coleman, Peter Martin, Jia Ruan, Richard Furman, Rebecca Elstrom, Ruben Niesvizky and John P Leonard. Low Dose Metronomic, Multidrug Therapy with the PEP-C (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Mantle Cell Lymphoma. Leukemia and Lymphoma. 2008 Mar; 49(3):447-450.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol. 2008 Mar 17. [Epub ahead of print]

Rutherford SC, Andemariam B, Philips SM, Elstrom RL, Chadburn A, Furman RR, Niesvizky R, Martin P, Fahey TJ, Coleman M, Goldsmith SJ, Leonard JP. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leuk Lymphoma. 2008 Apr;49(4):719-26.

Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Semin Hematol. 2008 Apr;45(2):126-32.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 May 15;112(10):2228-32.

He KL, Deora AB, Xiong H, Ling Q, Weksler BB, Niesvizky R, Hajjar KA. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p1. J Biol Chem. 2008 Jul 11;283(28):19192-200. Epub 2008 Apr 23.

Tomer Mark, Jessica Stern, Jessica Furst, April LaRow, Roger N Pearse, John Harpel, Tsiporah Shore, Michael Schuster, John P Leonard, Paul J Christos, Morton Coleman, Ruben Niesvizky. Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy On Stem Cell Collection In Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2008 Jul;14(7):795-8.

Ruben Niesvizky, Déborah M. Martínez-Baños. Aspirin as thromboprophylaxis in myeloma. Leuk Lymphoma. 2008 Aug;49(8):1646-7.

Ruben Niesvizky, Paul G. Richardson, S. Vincent Rajkumar, Pieter Sonneveld, Michael W. Schuster, Morton Coleman, David Irwin, Edward A. Stadtmauer, Thierry Facon, Jean-Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Jesús F. San Miguel, Mario Boccadoro, Jamie D. Cavenagh, William S. Dalton, Anthony L. Boral, Dixie-Lee Esseltine, Rachel Neuwirth, Kenneth C. Anderson, Joan Bladé. The relationship between quality of response to bortezomib and clinical benefit in the international, randomized, phase 3 APEX trial in relapsed multiple myeloma Br J Haematol. 2008 Sep;143(1):46-53. Epub 2008 Jul 31.

Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov;143(4):537-40. Epub 2008 Sep 6.

Tomer Mark, David Jayabalan, Richard Lent, Ethel Cesarman, Scott Ely, Roger Pearse, John Leonard, Morton Coleman, Selina Chen-Kiang, Ruben Niesvizky. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma Br J Haematol, 2008 Dec;143(5):654-60. Epub 2008 Oct 16.

Niesvizky R, Naib T, Coleman M. Lenalidomide in renal insufficiency - balancing the risks and benefits: response to Borrello. Br J Haematol. 2008 Dec 10. [Epub ahead of print]

Linda B. Baughn, Maurizio Di Liberto, Ruben Niesvizky, Hearn J. Cho, David Jayabalan, Joseph Lane, Fang Liu, and Selina Chen-Kiang. Cdk2 Phosphorylation of Smad2 Disrupts Transcriptional Regulation in TGF-Signaling in Resistant Primary Bone Marrow Myeloma Cells. Journal of Immunology 2009 Feb 15;182(4):1810-7.

Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009 Mar 10;27(8):1209-13

Edward A. Stadtmauer, Donna M. Weber, Ruben Niesvizky, Andrew Belch, H. Miles Prince, Jesus F. San Miguel, Thierry Facon, Marta Olesnyckyj, Zhinuan Yu, Jerome B. Zeldis, Robert D. Knight, Meletios A. Dimopoulos. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009 Jun;82(6):426-32. Epub 2009 Mar 19.

Asher Alban Chanan-Khan, Ruben Niesvizky, Raymond J. Hohl, Todd M. Zimmerman, Neal P. Christiansen, Gary J. Schiller, Natalie Callander, John Lister, Martin Oken, Sundar Jagannath. Randomized Phase III Study of Dexamethasone With or Without Oblimersen Sodium (G3139; Bcl-2 Antisense) for Patients with Advanced Multiple Myeloma. Leuk Lymphoma. 2009 Apr; 50(4): 559-65.

Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009 Sep;23(9):1545-56. Epub 2009 May 7

A Palumbo, O Sezer, R Kyle, J S Miguel, R Z Orlowski, P Moreau, R Niesvizky, G Morgan, R Comenzo, P Sonneveld, S Kumar, R Hajek, S Giralt, S Bringhen, K C Anderson, P G Richardson, M Cavo, F Davies, J Bladé, H Einsele, M A Dimopoulos, A Spencer, A Dispenzieri, T Reiman, K Shimizu, J H Lee, M Attal, M Boccadoro, M Mateos, W Chen, H Ludwig, D Joshua, J Chim, V Hungria, I Turesson, B G M Durie and S Lonial International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009 Oct;23(10):1716-30. Epub 2009 Jun 4.

Christine Chen, Donna E. Reece, David Siegel, Ruben Niesvizky, Ralph V. Boccia, Edward A. Stadtmauer, Rafat Abonour, David Irvin, Paul Richardson, Jeffrey Matous, Shaji Kumar, Nizar J. Bahlis, Sundar Jagannath, Melissa Alsina, Robert Vescio, Steven E. Coutre, Dennis Pietronigro, Robert Knight, Jerome B. Zeldis, and S. Vincent Rajkumar. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009 Jul;146(2):164-70. Epub 2009 May 26.

Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib- containing regimens. Blood. 2009 Aug 27;114(9):1729-35. Epub 2009 Jun 26.

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Oct;23(10):1904-12. Epub 2009 Jun 25.

Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov;23(11):2147-52. Epub 2009 Jul 23.

Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S. Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2009 Aug 15;15(16):5250-7. Epub 2009 Aug 11.

Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone. J Clin Oncol. 2010 Jan 1;28(1):132-5. Epub 2009 Nov 9.

Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun. 2010 Jan 29;10:4.

Mohamad Hussein, James R. Berenson, Ruben Niesvizky, Nikhil Munshi, Jeffrey Matous, Ronald Sobecks, Kate Harrop, Jonathan G. Drachman, and Nancy Whiting. A phase 1 multidose study of dacetuzumab (SGN-40; humanized anti-CD40 mAb) in patients with multiple myeloma. Haematologica. 2010 May;95(5):845-8. Epub 2010 Feb 4.

Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4

Berenson JR, Anderson K, Audell R, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol, [Epub ahead of print]5/2010

Ruben Niesvizky, Scott Ely, Sangeeta Aggarwal, Janice L Gabrilove, John J Wright, Selina Chen-Kiang, Joseph Sparano. Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Relapsed or Refractory Multiple Myeloma (MM). Cancer, 2010, Accepted for publication

Honors and Awards

The Leukemia and Lymphoma Society SCOR grant. Clinical Core. 2001-2005

Translational Research Grant: Awarded by CTEP:NCI. RFP S03-058 SAIC-Frederick

K23 Award: 1 K23 CA109260-01.EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA

2007 Investigator Award of the Michael Wolk Heart Foundation